Sucralose Exposure During Pregnancy Elevates Gestational Diabetes Risk via Gut Microbiota-Metabolic Axis in Mice

Jiajia Song1,2, Juhui He1,2, Zhaoxia Liang1,2

  • 1Department of Obstetrics, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China, zju.edu.cn.

Sucralose, a widely used nonnutritive artificial sweetener, has gained increasing popularity during pregnancy due to its low-calorie properties. The influence of sucralose on gestational diabetes mellitus (GDM) risk via alterations in gut microbiota composition is not yet well understood. This study sought to explore how gestational sucralose exposure influences GDM development in mice through gut microbiota dysbiosis, impaired intestinal barrier, and metabolic disorders. As an exploratory extension, we also preliminarily assessed early growth in offspring. In our experimental design, pregnant mice were administered sucralose solution to evaluate GDM incidence. Fecal samples were collected for 16S rRNA sequencing and untargeted metabolomic analysis. To establish causality, gut microbiota from sucralose-exposed pregnant mice was transplanted into control pregnant mice to assess subsequent GDM development and alterations in fecal 16S rRNA profiles. Additionally, we monitored postpartum glucose metabolism in sucralose-treated pregnant mice and tracked offspring body weight changes. Our results demonstrated that sucralose exposure significantly increased GDM incidence, accompanied by higher glucose levels and diminished insulin sensitivity. Furthermore, sucralose administration caused significant gut microbiota imbalance. It reduced beneficial taxa like Prevotellaceae UCG-001 and Lachnospiraceae UCG-001 while increasing the proinflammatory taxon Parasutterella. These changes strongly correlated with key fecal metabolites, including 5-aminopentanoic acid. Notably, maternal sucralose consumption during pregnancy also affected offspring body weight. These findings collectively indicate that gestational sucralose exposure elevates GDM risk in mice through the gut microbiota-metabolism axis, providing critical scientific evidence regarding the safety of low-calorie sweeteners in clinical applications during pregnancy.

Related Concept Videos

Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes: